Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer by Florus C. de Jong, Vera C. Rutten, Tahlita C. M. Zuiverloon, Dan Theodorescu

Get full text

Role of Bladder Cancer Metabolic Reprogramming in the Effectiveness of Immunotherapy by Mathijs P. Scholtes, Florus C. de Jong, Tahlita C. M. Zuiverloon, Dan Theodorescu

Get full text

The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer – a non-randomized phase II clinical trial by V. C. Rutten, Y. Salhi, G. J. Robbrecht, R. de Wit, G. J.L.H. van Leenders, T. C.M. Zuiverloon, J. L. Boormans

Get full text

Biomarker-Oriented Therapy in Bladder and Renal Cancer by Mathijs P. Scholtes, Arnout R. Alberts, Iris G. Iflé, Paul C. M. S. Verhagen, Astrid A. M. van der Veldt, Tahlita C. M. Zuiverloon

Get full text

Artificial Intelligence in Digital Pathology for Bladder Cancer: Hype or Hope? A Systematic Review by Farbod Khoraminia, Saul Fuster, Neel Kanwal, Mitchell Olislagers, Kjersti Engan, Geert J. L. H. van Leenders, Andrew P. Stubbs, Farhan Akram, Tahlita C. M. Zuiverloon

Get full text

Pathological T1 substaging corresponds with BCG-failure and improves the current EAU risk stratification for non-muscle invasive bladder cancer patients by F.C. De Jong, R. Hoedemaeker, V. Kvikstad, J.T. Mensink, E.R. Boevé, D.K.E. Van Der Schoot, J.L. Boormans, E.C. Zwarthoff, T.C.M. Zuiverloon

Get full text

Definitions of BCG-failure (EAU) vs BCG-unresponsive (FDA) in high-risk non-muscle invasive bladder cancer: A comparison of patient outcome by F.C. De Jong, R.F. Hoedemaeker, V. Kvikstad, J.T.M. Mensink, E.R. Boevé, D.K.E. Van Der Schoot, J.L. Boormans, E.C. Zwarthoff, T.C.M. Zuiverloon

Get full text

A Genomic Urine Assay for Surveillance of Patients with Bladder Cancer Treated with Radiotherapy by Florus C. de Jong, Iris G. Iflé, Angelique C. van der Made, Denise Kooper, Joep J. de Jong, Martine Franckena, Tahlita C.M. Zuiverloon, Wim van Criekinge, Luca Incrocci, Ellen C. Zwarthoff, Joost L. Boormans

Get full text

PD-L1 expression does not predict BCG-failure in a large cohort of high-risk non-muscle invasive bladder cancer patients by F.C. De Jong, R.F. Hoedemaeker, A.M. Van Der Made, V. Kvikstad, T.P.P. Van Den Bosch, E.R. Boevé, D.K.E. Van Der Schoot, J.L. Boormans, E.C. Zwarthoff, T.C.M. Zuiverloon

Get full text

Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections by J Alfred Witjes, Alina Vrieling, Mihai G Netea, Leo A B Joosten, Katja K H Aben, Sita H Vermeulen, Joost L Boormans, Antoine G van der Heijden, Boris Novakovic, Jelmer H van Puffelen, Liesbeth van Emst, Denise Kooper, Tahlita C M Zuiverloon, Ursula T H Oldenhof, Tessel E Galesloot, Lambertus A L M Kiemeney, Egbert Oosterwijk

Get full text